Partnerships

Memorial Sloan Kettering Cancer Center (MSKCC)In September 2014, SELLAS announced an exclusive global collaboration and exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSKCC) for the development, marketing and commercialization of MSKCC’s proprietary WT1 cancer immunotherapy.

WT1 is over-expressed in many human cancers, including most blood cancers and many solid tumors, including mesothelioma, and cancers of the ovary, lung, gastrointestinal tract, breast, and prostate. The National Cancer Institute recently ranked WT1 as the top target for cancer immunotherapy. MSKCC researchers have already shown the potential of this immunotherapy to safely immunize patients against the WT1 antigen in several clinical trials.

CordenPharma CordenPharma International is a full-service partner in the contract development & manufacturing of APIs, drug products, and associated packaging services. Through a network of fully-inspected cGMP facilities across Europe and the US organized under five technology platforms – Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, Small Molecules, Antibiotics - CordenPharma experts translate complex ideas at any stage of development into high-value products.

PolyPeptide Group The PolyPeptide Group is a contract manufacturing organization for peptides and peptide related molecules. The group is one of the world’s largest independent contract manufacturers of therapeutic peptides for the cosmetic, pharmaceutical and veterinary markets employing more than 450 people in six manufacturing sites located in France, India, Scandinavia and the USA. The company manufactures over one third of all approved peptide drug substances (22 of 62 approved products worldwide) accounting for over 25% of the sales of outsourced peptide therapeutics worldwide.

Merck & Co., Inc. 5 tumor indications
SELLAS entered into a Clinical Trial Collaboration and Supply Agreement for the conduct of a combination clinical trial Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada), whereby galinpepimut-S will be administered in combination with MSD's anti-PD-1 therapy pembrolizumab (Keytruda^®) in a Phase 1/2 trial enrolling patients with WT1-positive relapsed or refractory tumors in five cancer indications, including both hematologic malignancies and solid tumors. The study is expected to explore the following cancer indications: colorectal (arm enriched in but not exclusive to patients with microsatellite instability-low [MSI-L]), ovarian, small cell lung, triple-negative breast, and AML treated with hypomethylating agents.

Bristol-Myers Squibb (BMS) GPS plus nivolumab (ovarian cancer)
GPS plus nivolumab (MPM)
An investigator-sponsored trial (IST) was conducted with GPS in combination with nivolumab (Opdivo®; BMS). This Phase 1/2 clinical trial was an open label, single-center, investigator-sponsored, 10 patient study enrolling patients with ovarian cancer who relapsed at least once and returned to complete clinical remission after additional (first or subsequent) salvage chemotherapy.

An IST is being conducted with GPS in combination with nivolumab in patients with malignant pleural mesothelioma (MPM) at MSKCC. Enrollment is ongoing in this Phase 1 open-label clinical study of GPS in combination with nivolumab in patients with MPM who harbor relapsed or refractory disease after having received frontline standard of care multimodality therapy.

NPS + Trastuzumab, HER2 1+,2+ This investigator-sponsored trial was a clinical collaboration between the Company, Genentech/Roche, and the Henry M. Jackson Foundation. Genentech/Roche provided trastuzumab and partial funding for this trial.

NPS + Trastuzumab, HER2 3+Funding for this trial was awarded through the Congressionally Directed Medical Research Program (CDMRP), funded through the Department of Defense (DoD), via a Breast Cancer Research Program (BCRP) Breakthrough Award.

NPS, Ductal Carcinoma in Situ (DCIS) This trial is being run in collaboration with the National Cancer Institute (NCI). The University of Texas M.D. Anderson Cancer Center (MDACC) Phase I and II Chemoprevention Consortium is the lead for this multi-center trial. The Consortium is funded through the Division of Cancer Prevention at NCI, which will provide financial and administrative support for the trial. The Company is providing NPS.